Table 2 Characteristics of patients with GPA
From: Aberrant cytokine pattern of the nasal mucosa in granulomatosis with polyangiitis
Baseline cytokine secretion | Stimulation | |||||
|---|---|---|---|---|---|---|
n | % | n | % | |||
Biopsy proof | GPA | 12 | 60 | 7 | 70 | |
EULAR subgroups | generalized | 14 | 70 | 8 | 80 | |
early systemic | 5 | 25 | 1 | 10 | ||
local | 1 | 5 | 0 | 0 | ||
severe | 0 | 0 | 1 | 10 | ||
EULAR disease activity | remission | 6 | 30 | 2 | 20 | |
response | 0 | 0 | 1 | 10 | ||
relapse, minor | 8 | 40 | 2 | 20 | ||
relapse, major | 4 | 20 | 3 | 30 | ||
refractory | 1 | 5 | 0 | 0 | ||
low-activity | 1 | 5 | 2 | 20 | ||
Endoscopy: endonasal activity | none | 12 | 60 | 4 | 40 | |
mild | 7 | 35 | 4 | 40 | ||
moderate | 0 | 0 | 2 | 20 | ||
not evaluated | 1 | 5 | 0 | 0 | ||
Disease scores | median (range) | median (range) | ||||
DEI | 2 (0 to 5) | 2 (0 to 5) | ||||
BVAS-1 | 3 (0 to 13) | 1.5 (0 to 12) | ||||
BVAS-2 | 0 (0 to 4) | 0 (0 to 4) | ||||
VDI | 0.5 (0 to 3) | 2 (0 to 4) | ||||
Immunomodulating therapy | n (%) | mean value (mg) | n (%) | mean value (mg) | ||
prednisolone | 19 (95) | 12.89 | 9 (90) | 10.67 | ||
methotrexate | 10 (50) | 22.25 | 2 (20) | 20 | ||
cyclophosphamide regular | 3 (15) | 133.33 | 1 (10) | 100 | ||
cyclophosphamide bolus | 2 (10) | 1000 | 2 (20) | 1000 | ||
azathioprine | 2 (10) | 125 | 2 (20) | 125 | ||
leflunomide | 2 (10) | 25 | 2 (20) | 25 | ||
mycophenolate mofetil | 1 (5) | 2000 | 0 (0) | 0 | ||
cummulative cyclophosphamide | 6 (30) | 45.17 (g) | 8 (80) | 14.88 (g) | ||